Mesenchymal Stem Cells to Treat Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT02302599

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02302599
Other papers using this trial's data
  • Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial Stem cell research & therapy, 2022-05-03 DOI, PubMed 35505375, PMC9066971 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02302599. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (actual); primary completion 2020-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mesenchymal Stem Cells to Treat Type 2 Diabetes
Acronym
UC-MSCs
Condition
Mesenchymal Stem Cells
Intervention (Biological)
Umbilical cord mesenchymal stem cells
Intervention (Biological)
Controlled suspension liquid
Lead sponsor
Chinese PLA General Hospital (class: other)

Record details

Record id
cardio:ct-nct02302599
Content hash
99f1bc57cfa9e8e3e38bd30d805194780a61180a8ed10217dd1659efde4312a8